Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Thaker

Showing results (191-200 of 237) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Molecular Cancer Therapeutics|November 28, 2018
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerJeanne M Quinn, Molly M Greenwade, Marguerite L Palisoul, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
Gynecologic Oncology|November 13, 2025
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinomaRachel L Furuya, Whitney Grither, Mark G Evans, et al.
Gynecologic Oncology|April 18, 2013
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancerIsrael Zighelboim, Jason D Wright, Feng Gao, et al.
Oncotarget|April 29, 2016
SSRI use and clinical outcomes in epithelial ovarian cancerDesiré K Christensen, Guillermo N Armaiz-Pena, Edgardo Ramirez, et al.
Gynecologic Oncology|September 8, 2018
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growthKathryn A Mills, S Tanner Roach, Jeanne M Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2018
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group StudyMartee L Hensley, Danielle Enserro, Helen Hatcher, et al.
Cancers|December 10, 2021
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous CancerMichael D Toboni, Elena Lomonosova, Shaina F Bruce, et al.
Oncotarget|October 21, 2016
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancerLaura M Divine, Mai R Nguyen, Eric Meller, et al.
Pageof 24

Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Molecular Cancer Therapeutics|November 28, 2018
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerJeanne M Quinn, Molly M Greenwade, Marguerite L Palisoul, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
Gynecologic Oncology|November 13, 2025
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinomaRachel L Furuya, Whitney Grither, Mark G Evans, et al.
Gynecologic Oncology|April 18, 2013
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancerIsrael Zighelboim, Jason D Wright, Feng Gao, et al.
Oncotarget|April 29, 2016
SSRI use and clinical outcomes in epithelial ovarian cancerDesiré K Christensen, Guillermo N Armaiz-Pena, Edgardo Ramirez, et al.
Gynecologic Oncology|September 8, 2018
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growthKathryn A Mills, S Tanner Roach, Jeanne M Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2018
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group StudyMartee L Hensley, Danielle Enserro, Helen Hatcher, et al.
Cancers|December 10, 2021
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous CancerMichael D Toboni, Elena Lomonosova, Shaina F Bruce, et al.
Oncotarget|October 21, 2016
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancerLaura M Divine, Mai R Nguyen, Eric Meller, et al.
Pageof 24